From:  Role of brain cholecystokinin in neuronal homeostasis: rediscovering novel functions of an old neuropeptide

 Translational gaps on the psychiatry/analgesic potential of CCK2r antagonists

Preclinical evidenceClinical trials
Compound (dosage) lengthOutcomesReferencesCompound (dosage) lengthOutcomesReferences
CI-988 (0.001–10.0 mg/kg, i.p.)
Acute
Anxiolytic-like action in rats elevated the X-maze, rat social interaction test, and mouse light/dark shuttle box[208]CI-988 (300 mg/day, thrice daily)
Four weeks
No anxiolytic effect in general anxiety disorder[23]
CI-988 (100 mg/day, thrice daily)
Six weeks
No anxiolytic effect in panic disorder[25]
L-365,260 (3.2, 10, and 32 mg/kg, i.p.)
Acute
Antipanic-like effects in rats receiving brain stimulation in the dorsal PAG[209]L-365,260 (30 mg/day, four times daily)
Six weeks
No anxiolytic effect in panic disorder[24]
CI-988 and L-365,260 (8.9, 0.16, and 0.25 μmol/kg, i.p.)
Acute
Anxiolytic-like action in rats elevated the X-maze[210]L-365,260 (10–50 mg)
Acute
CCK-4 panicogenic effects are antagonized by L-365,260 in panic disorder patients[211]
L-365,260 (0.1 and 0.5 mg/kg, s.c.)
Acute
Enhancement of the analgesia induced by a submaximal dose of morphine[212]L-365,260 (10 mg and 40 mg thrice daily)
Two weeks
L-365,260 fails to augment morphine-induced analgesia in chronic neuropathic pain[26]

i.p.: intraperitoneal; s.c.: subcutaneous. PAG: periaqueductal grey; CCK-4: cholecystokinin tetrapeptide